Nineteen Companies. Twenty-One Investigations. Zero Admissions of Wrongdoing.

For those who still need proof that the pharmaceutical industry views human health as a commodity and patients as revenue streams, a new review published in the Journal of Law, Medicine & Ethics just handed it to you—documented, sourced, and damning. The study abstract declared:

“Reported bribes amounted to about US $12.6 million, with sanctions exceeding US $1.1 billion. Government officials, regulatory authorities, and healthcare providers were bribed through cash, gifts, luxury travel, and fraudulent research to gain market access, increase sales, or influence prescribing. These findings underscore the systemic nature of bribery in the pharmaceutical sector and call for stronger oversight and accountability to protect public trust and equitable medicine access.”

Researchers at the University of Toronto spent years combing through reports from the OECD Working Group on Bribery, tracking pharmaceutical bribery cases across five countries spanning two decades. What they found wasn’t shocking to anyone paying attention. It was, however, finally on paper. Nineteen companies. Twenty-one investigations. Bribes funneled through shell companies, sham clinical studies, fake consulting contracts, charitable foundations, and spa weekends billed as medical education. At least $12.6 million in documented illicit payments. Over $1.1 billion in sanctions—paid, in most cases, without a single admission of wrongdoing.

Read that last part again. Over a billion dollars in penalties, and virtually nobody had to state that they did anything wrong.

The names on this list aren’t marginal operators. No indeed. Novartis. Pfizer. Johnson & Johnson. Eli Lilly. Teva. GlaxoSmithKline. Bristol-Myers Squibb. Novo Nordisk. These are the companies whose products sit in your medicine cabinet, whose reps visit your doctor’s office, and whose lobbyists write the legislation meant to regulate them. In Greece, Novartis paid for physicians to attend international conferences—then threatened to cut off funding if prescription quotas for their drugs weren’t met. In Russia, Eli Lilly (which makes Mounjaro) funneled over $11 million through offshore shell companies tied to government officials and members of parliament, all disguised as “marketing services.” In China, Pfizer created a points program letting doctors earn gifts based on how many of their medications they prescribed. In Poland, Eli Lilly transferred nearly $40,000 to a health official’s personal charity in exchange for getting their drugs onto the government reimbursement list—then recorded it as payment for computer purchases and conferences that never happened.

Make no mistake: these aren’t rogue employees going off-script. Instead, they are seasoned criminals intent on deception. The examination was clear on this critical point, reporting that bribery was routinely approved or knowingly tolerated by senior management. Specifically, executives signed off on falsified invoices. Compliance reviews flagged the red flags and were ignored. Internal warnings circulated and disappeared. This was operational strategy, not misconduct. The difference matters. Highlighting the corrupt United Nations involvement in the scheme, the analysis revealed:

“Under the United Nations (UN) Oil for Food Program, pharmaceutical companies were required to sell products to Iraq by way of an UN-supervised system. This review identified firms manipulating contract pricing, inflating costs and redirecting the excess funds as disguised “agent commissions” to Iraqi ministries. These payments were falsely recorded as legitimate fees or marketing costs while the companies recovered the padded amounts from the UN escrow fund. Johnson & Johnson also paid $857,387 in kickbacks disguised as agent commissions to secure contracts with Iraq’s Ministry of Health (Kimadia).

Additionally, Johnson & Johnson inflated contract prices by 10% in Iraq by disguising the overcharge as “promotional activities” and directing the funds to Iraqi officials. Further, Novo Nordisk paid $1.44 million and authorized an additional $1.32 million in inflated commissions to funnel such bribes. In another case prosecuted in Italy, an unidentified pharmaceutical company was accused of paying EUR 144,660 in bribes under the program, but charges were later dismissed due to the statute of limitations.”

Lead author Professor Jillian Kohler didn’t mince words. Corruption, she said, creates barriers to health services, compromises the quality of care, and in the worst cases—kills. That’s not activist language. That’s a University of Toronto pharmacologist summarizing what the evidence shows.

Johnson & Johnson paid $70 million in penalties the same year it reported $65 billion in revenue. Teva handed over $519 million to settle eleven years of documented bribery across Russia, Ukraine, and Mexico—without admitting wrongdoing—and called it putting the matter behind them. A study published this year in JAMA Network Open tracked U.S. pharmaceutical kickback fines over 25 years and found companies paid penalties amounting to 2.2% of the revenue tied to the violations. $10.2 billion in fines. $459 billion in implicated sales. So no, the penalties aren’t a deterrent. They’re overhead.

This is the industry that brought us the opioid crisis. The one that spent decades suppressing data on antidepressant risks in children. The one whose COVID-19 mRNA rollout was pushed through at a speed that bypassed the kind of long-term safety data any other drug would have required—and then watched as governments worldwide mandated it, indemnified the manufacturers, and dismissed every question as misinformation. The pattern isn’t new. The arrogance isn’t new. What’s new is a peer-reviewed paper in a major legal and medical journal calling it what it is—systemic, institutional, and deliberately concealed.

Doctors are supposed to prescribe drugs based on evidence and patient need. Regulators are supposed to approve drugs based on safety and efficacy. When both of those functions are quietly purchasable, the entire premise of modern medicine collapses. What’s left is what we have today—a hugely profitable business model dressed up in a white coat that thrives when we remain unwell.

The researchers are calling for structural reform—whistleblower protections, mandatory disclosure of industry payments, independent clinical trial funding, and stronger international enforcement. These are all extremely reasonable and necessary and are each completely dependent on the political will of governments that have spent decades taking money from the same industry they’re supposed to regulate. Until we see real change, don’t hold your breath waiting for the system to fix itself. The people running it built it this way on purpose.